Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CogDiss:
Citadel securities fined for fronting running OTC equity trading by changing their internal systems to
I suppose that’s what ex-government officials do — sell their connections, work their Rolodex (how old are we Jerry? Do you still get milk delivery to the house? I have a Royal typewriter I still bang out letters to friends on — it’s eccentric and my friends think it’s a hoot.)
It is an interesting coincidence that he chose Latvia and the Ukraine, ie, within “spitting” distance of Russia (‘cause of course we have to spit at them when we have a chance). But maybe it’s just that, a strange coincidence. Though you’d think he’d try to wheedle his way onto the board of Total so he could have a reason to go to Paris at least. Or some bank in London — so many to choose from.
I’m sure he has his reasons—Latvia in the spring is no doubt charming. And there’s a little action on the side that he can read about while having his morning coffee at The Coffee Inn in Riga.
Thanks Doc Logic. As Edison said, it’s 1% inspiration, 99% perspiration. I’ve been researching and thinking about cancer treatment options for 22 years, somewhat obsessively, more or less. No stone unturned. The last 7 or so years has been especially promising as mainstream science has begun to confirm some old ideas. Certainly immune-oncology is a focus but also epigenetics, cancer metabolism, embryological/stem cell and even what might be classified as chemotherapeutic approaches, in a less harsh manner.
I hope to share more ultimately.
Yes, no doubt a dire situation with tough choices ahead.
If one decides to pursue treatment with the hope of life extension, these seem like the best options to investigate. Toxicity tends to be lower with this approach as well.
It’s things like this that remind us of the preciousness and pain of life, as well as how short it ultimately is. I pray that God be with them in this time of need and that they find the strength and clarity of mind to deal with this great trial they face.
Given that their standard options are reduced to a single one, apparently without a lot of hope (though it will buy much needed time), it seems like going outside the box is something to consider seriously. It is a difficult path, with many obstacles, one of which is a lack of time to work through an overwhelming number of options and information. Another is a lack of support to pursue rational options. I hope the following gives them a good start if they decide to leave no stone unturned — something much easier said than done.
The documentary, Surviving Terminal Cancer, provides the rationale behind using existing drugs meant for other illnesses like diabetes, malaria, etc, and repurposing them in a synergistic cocktail against cancer.
https://www.survivingterminalcancer.com
The use of repurposed drugs is being promoted in England at the Care Oncology Clinic. They help patients get the drugs needed for various forms of cancer.
https://careoncology.com/coc-glioblastoma-treatment/
They also are running trials using the approach. They just published (June, 2020) the results of a trial with 95 patients in Glioblastoma in which the use of repurposed drugs in addition to standard of care nearly doubled median survival. I just found this trial result this morning and so can’t comment on its strengths or shortcomings but it is not unexpected, given what we know about cancer mechanisms and the potential for a multi-targeted approach.
https://www.frontiersin.org/articles/10.3389/fphar.2019.00681/full
Quick comment on these kind of statistics. Individuals are not the group. It is incorrect to think “I have x months to live,” though that “x” does give one a read on how serious the situation is. The idea is to do everything one can to “move the curve” in a positive direction as well as increase one’s odds of being in the long survival tail to the right side of the curve. As a simple example, breast cancer patients who exercise have significantly better outcomes than those who don’t. Therefore, time to get moving, even if your oncologist for some mystifying reason is unaware of it or never mentions it. There are many other things like that which one can do to increase the odds.
Care Oncology Clinic’s website mentions that one doesn’t have to be in the UK in order for them to work with you.
Travis Christofferson, author of “Tripping Over the Truth: How the Metabolic Theory of Cancer is Overturning One of Medicine’s Most Entrenched Paradigms,” is heading up a similar clinic in the US that is essentially the US branch of the UK clinic.
https://www.google.com/amp/s/rapidcityjournal.com/news/local/new-rapid-city-clinic-puts-generic-drugs-to-use-to-help-fight-cancer/article_886b650b-a33d-5dcd-9837-03d67d9f93c1.amp.html
https://www.amazon.com/Tripping-over-Truth-Overturning-Entrenched/dp/1603587292
Oren Becher is a specialist at Northwestern who is studying DIPG. He recently mentioned looking at repurposing existing drugs to impact the disease. He might have a new lead or two based on his new research findings on the biology of DIPG.
https://news.feinberg.northwestern.edu/2019/05/mutations-synergize-in-pediatric-brain-cancer/
As an example which supports the overall concept of using existing drugs for diseases other than for what they were originally intended, the approach is being explored against covid-19 by a team of researchers, led by a man who saved his life using a repurposed drug against Castleman’s disease (which induces life threatening cytokine storms):
https://www.cnn.com/2020/06/27/health/coronavirus-treatment-fajgenbaum-drug-review-scn-wellness/index.html
Two additional resources to consider contacting are Ben Williams, prominently mentioned in the documentary. He is known to help patients navigate their options regarding brain cancers and must be considered a world expert on brain cancers at this point. He wrote a book with the same title as the documentary but it is somewhat out of date since he’s survived his terminal diagnosis by 20+ years. There are updated notes online but I would try to contact him directly since he could provide quicker, more targeted advice.
The other resource is Jane McLelland, author of “How to Starve Cancer.” She has overcome two forms of cancer using repurposed drug combinations as well as other approaches. Her perspective seems to be the broadest of all those working in this area while still being as evidence-based as is possible in a world which stands in the way of all options that aren’t patentable. She has a Facebook page with a very active group of followers.
One of the toughest things is finding a doctor who supports out-of-the-box approaches. These resources may be a good source for references to such doctors.
Tryn, I agree on taking the biggest loss to get the biggest deduction on income to reduce taxes, which also means you’ll sell fewer shares to snag the loss.
Hoping you haven’t bought any shares in the last 30 days or you’ll have a wash sale and can’t deduct the loss this year.
Remember you can only deduct $3000 a year in net capital losses, though you can carry the excess loss forward and use the remainder next year.
Why are taxes so complicated?
Oh yeah, never mind, I remember—we live in an civil oligarchy that is set up for tax avoidance by billionaires. You’ll know you’ve made it when to have a team of tax accounts working for you full time.
It seems like the Healios trials completing enrollment are the known events. The Japanese stroke trial (TREASURE) should complete enrollment by end of 2020, maybe slightly earlier (someone on Reddit suggests mid-November by reading Gil Vanbokken tea leaf comments). The Japanese ARDS trial with additional covid patients (ONE-BRIDGE) is listed on clinicaltrials.gov to complete in March, 2021. Healios has suggested they are essentially on schedule.
Unfortunately, I haven’t saved off the links to this. I watched a Healios investor presentation a few months ago but can’t find it now.
Athersys has suggested that they are in conversations with potential European pharmas to partner on various possibilities, especially the stroke indication. That’s the big kahuna that will shoot Athersys into the stratosphere if successful. It is my main focus with them, though earlier Healios results could be significant catalysts.
Novartis Paid Doctors Kickbacks—Will Pay $678 Million Settlement
Settlement reached yesterday:
Novartis Paid Doctors Kickbacks—Will Pay $678 Million Settlement
Settlement reached yesterday:
I can imagine German clinicians in the trial coming to the conclusion that “they’re all living longer” and having an ethical concern over giving placebo.
But what was announced about their thinking or behavior? I’m trying to understand what happened before any speculation on motivation is added. Did they just stop recruiting into the trial without announcing why? Was the partial hold concurrent with or after any action they took?
Yes, DL, I thought the same thing as you did when I read the 10Q (not PR as I misspoke) the day it came out, ie, lawyerspeak to create a cloud of uncertainty.
I thought about adding that caveat to my post but I felt that the amused contempt interpretation makes as much if not more sense, knowing that we’d be deciphering it for days afterwards on the mm.
Always appreciate your thoughts even if I don’t always agree (as well as your riddle solving skills. ).
DL, I believe you have decoded the riddle correctly. The fact that they saw fit to include such an obvious monstrosity in a PR signals an amused contempt for its readers.
Kenneth Traub bought 140,000 shares in three days (June 22 -24th). He’s a director on the board of Athersys. That’s an investment of $322,175 this week!
Insiders selling don’t mean much in and of itself (Muffy may need some orthodontia and its time for a bigger boat) but insiders essentially doubling their position is a big vote of confidence.
https://www.sec.gov/Archives/edgar/data/1232602/000136814820000085/xslF345X03/wf-form4_159303294449645.xml
The Celgene story kind of kills me, though I know it shouldn’t. I was heavily researching cancer treatments (specifically for breast cancer) back when they were reporting very promising early data in blood cancers. I saw multiple examples of thalidomide’s efficacy but assumed the negative story line the writers of the stories would always include would kill its chances.
I wasn’t really in a position sit back and think through the situation. I had purposely sold all stocks I owned so I could solely focus on finding promising breast cancer treatments. A crazy missed opportunity but in actually it wasn’t an opportunity for me at that point in my life.
Those Chatham House lectures ended up being leaked — which really sux because a key feature of Chatham House discussions is to be off-the-record to encourage unvarnished honesty among ruling elites.
Thanks! Looks like they’re getting ready to move some product in the future
Maybe the opposite—he might have driven them mad.
Either way, The Odyssey is very much worth reading, impossible to recommend too highly, other than the Bible. Though at least with The Odyssey, you don’t need four versions and a dozen commentaries to navigate it without shipwreck.
Iwasadiver, appreciate your response. I haven’t looked into the details on HCQ enough to make a firm judgment but I suspect zinc is important, perhaps critical, to the protocol, as well as zpac. There seem to be doctors having success but of course the trial results are muddy. I wouldn’t be surprised if there was monkey business going on with some of the trials. I hope to provide a couple of examples in the future.
Time will tell and it will be useful in updating our models of the world if necessary when the truth is finally nailed down.
BTW, I don’t have much good to say about the current state of medicine, in general. However, I believe that acute care, which you specialize in, is one of the few areas that stand out positively. Obviously if I’ve been shot in one of these crazy riots I would try to stumble towards your ER and collapse in the doorway looking for you to save my life.
It’s in chronic illness, especially, but not limited to cancer care, that the edifice is rotten top to bottom. It’s been a process that goes back over 100 years so most doctors aren’t even aware of the situation. It’s just the air we breathe these days, and if you only know the San Fernando Valley it seems like the way things should be.
I believe he was thinking of James Joyce, not Homer, but was disappointed that it didn’t contain the requisite smut.
Thanks for sharing! Didn’t realize how much money BARDA was handing out. Many in the hundreds of thousands or few millions but there were several from $430 million to $1.2 billion!
ATHX should snag some of the slop at the government trough eventually — apparently still in progress.
They’ve worked with BARDA in the past, on treating radiation burns.
I missed the post - what was the actual job title or responsibilities that got filled?
Some of us have grown beards that are dragging the floor while waiting for this trial to finally read out (closing in on 10 years here), so predictions of “kicking the can,” if that’s how you want to classify it, have been a safe one to make.
However, other than some final short term delays beyond the putative timeline laid out in April, which seemed to point towards early July then, I’m having a hard time seeing a delay that goes beyond mid-September (my guess in the prediction derby). My prediction was based on normal stupid shit that happens that could cause delay (ie, no ill intent involved).
What are some concrete examples of rabbits LP could pull out of her hat that would delay TLD beyond September? I’m lacking in imagination or experience here, yet you, Ex and others seem pretty confident of extended delay, even though the landing gear is down and we’ve begun our descent.
Iwasadiver, was wondering about the protocol actually used in hospitals. Is it somewhat standardized and can you give us an idea of the dosages used in the elements of the protocol?
I have a science research background (organic chemistry and pharmacology) though I left the field to pursue other interests more technology focused. I’m interested in following how the controversy plays itself out over the ensuing months, and the actual protocol used seems to be one of the areas of contention.
Fine Dude. I shouldn’t have expected that you could engage in actual discourse.
Before I begin, I want to say that a appreciate the more measured nature of your last response. I don’t intend any low blows in what follows.
You say you’re not making things up. I get the impression it’s happened multiple times in this thread. Here are a just a few examples.
Brilliant satire—passing on to friends!
I see you have an eye for detail. To motivate you to read this long post, here are two drug reps mentioned in the articles below.
The first article is the one that inspired my “worldwide network of blond drug reps” comment. I was doing a lot of research on cancer treatment options around the time this came out. I came across several hundred articles detailing the corrupt practices of the medical-pharmaceutical-regulatory complex — mostly by just reading the cancer treatment related news diligently every day. One reason for my jaundiced view.
Double entredres abound.
Gimme an Rx! Cheerleaders Pep Up Drug Sales
Run your machine learning algorithms on Bill Burr routines. They’re much better than the schoolyard banter your feeding yourself.
Upgrade your software dude! You’re stuck in a infinite loop.
A $4 to $20 billion apples to pineapples question?
Genmab is already a roughly $20 billion company. (Anchor that price everyone!)
It’s a development and commercialization deal worth almost $4 Billion for 3 early stage bispecific antibodies for blood cancers that haven’t even made it to phase 1 trials.
I thought it was a generous deal, given GMAB shares profits 50:50 in US and Japan, potentially worth billions, and gets up to 26% royalties from ABBV using its muscle and worldwide network of blond drug reps to sell to the rest of the world.